Eli Lilly and Company CEDEAR (LLYD)
BCBA
Closed
Aug 21, 2026
Day's Range
23.0552 wk Range
12.20Overview - LLYD - Eli Lilly and Company CEDEAR
Key Statistics
Valuation
Enterprise Value
677.47B
Price / Book
‪18.64‬
EV / EBITDA
‪16.24‬
Profitability
Gross Margin
‪31.46%‬
Profit Margin
‪33.52%‬
Operating Margin
‪54.22%‬
Return on Assets
‪20.35%‬
Return on Equity
‪102.28%‬
Ownership
Float
26.93B
Held by Insiders
‪0.00%‬
Held by Institutions
‪0.00%‬
Price stats
Beta
‪0.50‬
50-Day Avg
‪21.80‬
200-Day Avg
‪19.34‬
Dividends
Frequency
Quarterly
Peers - LLYD - Eli Lilly and Company CEDEAR
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on BCBA.
- LLYDBCBAEli Lilly and Company CEDEAR+46.19%52-week change—P/E (Trailing)‪33.52%‬Profit Margin
- SANBCBABanco Santander, S.A. CEDEAR+43.62%52-week change59.10P/E (Trailing)‪33.46%‬Profit Margin
- JNJBCBAJohnson & Johnson CEDEAR+44.54%52-week change11.12P/E (Trailing)‪21.48%‬Profit Margin
- BMYBCBABristol-Myers Squibb Co.+40.10%52-week change5.14P/E (Trailing)‪18.87%‬Profit Margin
- MRKBCBAMerck & Co., Inc. CEDEAR+52.72%52-week change2.59P/E (Trailing)‪4.76%‬Profit Margin
- BIIBBCBABiogen Inc. CEDEAR+47.55%52-week change3.02P/E (Trailing)‪8.32%‬Profit Margin
- AMGNBCBAAmgen Inc.+42.86%52-week change0.19P/E (Trailing)‪22.95%‬Profit Margin
Profile Summary - LLYD - Eli Lilly and Company CEDEAR
About
Eli Lilly and Company CEDEAR is a depositary certificate representing shares of a leading global biopharmaceutical firm through the Argentine market infrastructure. Its primary purpose is to provide local investors access, in local custody and settlement, to the economic rights of Eli Lilly and Company, including…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
